Published in Leuk Res on December 01, 2003
The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. Br J Cancer (2005) 1.41
Gallium nitrate is efficacious in murine models of tuberculosis and inhibits key bacterial Fe-dependent enzymes. Antimicrob Agents Chemother (2013) 0.82
Biochemical modulation of aracytidine (Ara-C) effects by GTI-2040, a ribonucleotide reductase inhibitor, in K562 human leukemia cells. AAPS J (2010) 0.80
Gemcitabine and carboplatin demonstrate synergistic cytotoxicity in cervical cancer cells by inhibiting DNA synthesis and increasing cell apoptosis. Onco Targets Ther (2013) 0.79
Digalloylresveratrol, a novel resveratrol analog inhibits the growth of human pancreatic cancer cells. Invest New Drugs (2013) 0.77
Understanding the molecular interactions of different radical scavengers with ribonucleotide reductase M2 (hRRM2) domain: opening the gates and gaining access. J Comput Aided Mol Des (2012) 0.75
Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet (2002) 5.55
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res (2006) 4.15
A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia. Blood (2012) 2.65
Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood (2006) 2.18
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood (2007) 2.15
A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. Blood (2008) 1.90
Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro. Cancer Res (2009) 1.71
New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia. J Clin Oncol (2009) 1.68
Regulation of leukemic cell adhesion, proliferation, and survival by beta-catenin. Blood (2002) 1.65
Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis. Cancer Cell (2004) 1.65
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood (2006) 1.59
Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies. Leuk Res (2007) 1.57
Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. J Biol Chem (2007) 1.51
A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. Blood (2007) 1.48
Minimal residual disease in acute myeloid leukaemia. Nat Rev Clin Oncol (2013) 1.44
Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. Blood (2005) 1.38
Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw (2008) 1.36
Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw (2012) 1.35
Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia. BMC Cancer (2004) 1.31
Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. J Clin Oncol (2009) 1.23
Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. Blood (2011) 1.20
Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution. Biol Blood Marrow Transplant (2011) 1.17
Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation. Leuk Lymphoma (2010) 1.13
Central role of Fas-associated death domain protein in apoptosis induction by the mitogen-activated protein kinase kinase inhibitor CI-1040 (PD184352) in acute lymphocytic leukemia cells in vitro. J Biol Chem (2003) 1.12
Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells. Blood (2003) 1.10
Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies. Cancer Res (2009) 1.09
Flavopiridol induces BCL-2 expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemia. Leuk Lymphoma (2011) 1.07
CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo. Haematologica (2013) 1.06
Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia. Leuk Res (2004) 1.04
Exploiting cellular pathways to develop new treatment strategies for AML. Cancer Treat Rev (2010) 1.03
Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells in vitro. Clin Cancer Res (2012) 1.01
Genomic mechanisms of p210BCR-ABL signaling: induction of heat shock protein 70 through the GATA response element confers resistance to paclitaxel-induced apoptosis. J Biol Chem (2004) 0.96
Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients. Clin Cancer Res (2003) 0.94
The clinically relevant pharmacogenomic changes in acute myelogenous leukemia. Pharmacogenomics (2012) 0.94
CXCR4 chemokine receptor signaling induces apoptosis in acute myeloid leukemia cells via regulation of the Bcl-2 family members Bcl-XL, Noxa, and Bak. J Biol Chem (2013) 0.93
Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells. Blood (2010) 0.92
Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia. Haematologica (2011) 0.92
Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia. Epigenetics (2010) 0.91
Lessons from tumor reversion for cancer treatment. Curr Opin Oncol (2013) 0.89
Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy. Blood (2003) 0.89
Protein kinase Cbeta modulates ligand-induced cell surface death receptor accumulation: a mechanistic basis for enzastaurin-death ligand synergy. J Biol Chem (2009) 0.88
Performance and clinical evaluation of a sensitive multiplex assay for the rapid detection of common NPM1 mutations. J Mol Diagn (2010) 0.88
Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia. Clin Cancer Res (2005) 0.88
Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF. Leuk Res (2010) 0.87
Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplant. Am J Hematol (2014) 0.87
Histone deacetylase inhibitor pharmacodynamic analysis by multiparameter flow cytometry. Ann Clin Lab Sci (2005) 0.86
New agents in acute myeloid leukemia: beyond cytarabine and anthracyclines. Curr Oncol Rep (2009) 0.86
Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases. Cancer (2003) 0.86
Metabolic and electrochemical mechanisms of dimeric naphthoquinones cytotoxicity in breast cancer cells. Bioorg Med Chem (2011) 0.84
Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies. Cancer Chemother Pharmacol (2012) 0.84
New considerations in the design of clinical trials for the treatment of acute leukemia. Clin Investig (Lond) (2011) 0.84
Novel postremission strategies in adults with acute myeloid leukemia. Curr Opin Hematol (2009) 0.83
The state of the union on treatment of acute myeloid leukemia. Leuk Lymphoma (2014) 0.82
Osteoblasts protect AML cells from SDF-1-induced apoptosis. J Cell Biochem (2014) 0.82
Development of therapeutic agents for older patients with acute myelogenous leukemia. Curr Opin Investig Drugs (2010) 0.81
Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemia. Am J Hematol (2005) 0.81
Poly(ADP-ribose) polymerase inhibitors sensitize cancer cells to death receptor-mediated apoptosis by enhancing death receptor expression. J Biol Chem (2014) 0.80
A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia. Leuk Res (2005) 0.80
Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer. Invest New Drugs (2006) 0.80
A rapid and sensitive method for determination of veliparib (ABT-888), in human plasma, bone marrow cells and supernatant by using LC/MS/MS. J Pharm Biomed Anal (2009) 0.80
PMLRARα binds to Fas and suppresses Fas-mediated apoptosis through recruiting c-FLIP in vivo. Blood (2011) 0.79
Farnesyl transferase inhibitors in myeloid malignancies. Blood Rev (2003) 0.79
Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells. Haematologica (2013) 0.79
Personalized therapy for acute myeloid leukemia. Cancer Discov (2013) 0.79
Farnesyltransferase inhibitors and myeloid malignancies: phase I evidence of Zarnestra activity in high-risk leukemias. Semin Hematol (2002) 0.78
New agents in the treatment of acute myeloid leukemia: a snapshot of signal transduction modulation. Clin Adv Hematol Oncol (2005) 0.78
KLFs and ATRA-induced differentiation: new pathways for exploitation. Leuk Res (2011) 0.77
A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms. Haematologica (2013) 0.77
What are the endpoints of therapy for acute leukemias? Old definitions and new challenges. Clin Lymphoma Myeloma (2009) 0.76
CD30 in myeloid malignancies: hitting the bull's-eye with an available dart. Leuk Lymphoma (2012) 0.75
Curing acute myelogenous leukemia: still a major challenge. Leuk Res (2005) 0.75
Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias. Br J Haematol (2012) 0.75
Developmental clinical trials: building one step at a time. Leuk Res (2006) 0.75
Farnesyl transferase inhibitors in myeloid disorders. Oncology (Williston Park) (2005) 0.75
The long road to a cure for acute myelocytic leukemia: from intensity to specificity. J Clin Oncol (2008) 0.75
Exploiting oxidative damage to overcome resistance. Leuk Res (2006) 0.75